These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
33. High-sensitivity C-reactive protein, low-density lipoprotein cholesterol and cardiovascular outcomes in patients with type 2 diabetes in the EXAMINE (Examination of Cardiovascular Outcomes with Alogliptin versus Standard of Care) trial. Hwang YC; Morrow DA; Cannon CP; Liu Y; Bergenstal R; Heller S; Mehta C; Cushman W; Bakris GL; Zannad F; White WB Diabetes Obes Metab; 2018 Mar; 20(3):654-659. PubMed ID: 29064626 [TBL] [Abstract][Full Text] [Related]
34. Relationship between small dense low density lipoprotein and cardiovascular events in patients with acute coronary syndrome undergoing percutaneous coronary intervention. Zhang J; He L BMC Cardiovasc Disord; 2021 Apr; 21(1):169. PubMed ID: 33845772 [TBL] [Abstract][Full Text] [Related]
35. Association of lipoprotein(a) level with short- and long-term outcomes after CABG: The role of lipoprotein apheresis. Ezhov MV; Afanasieva OI; Il'ina LN; Safarova MS; Adamova IY; Matchin YG; Konovalov GA; Akchurin RS; Pokrovsky SN Atheroscler Suppl; 2017 Nov; 30():187-192. PubMed ID: 29096836 [TBL] [Abstract][Full Text] [Related]
36. Lipoprotein(a) screening in young and middle-aged patients presenting with acute coronary syndrome. Jubran A; Zetser A; Zafrir B Cardiol J; 2019; 26(5):511-518. PubMed ID: 30234895 [TBL] [Abstract][Full Text] [Related]
37. Baseline levels of serum high sensitivity C reactive protein and lipids in predicting the residual risk of cardiovascular events in Chinese population with stable coronary artery disease: a prospective cohort study. Dai W; Zhang Z; Zhao S Lipids Health Dis; 2018 Dec; 17(1):273. PubMed ID: 30509306 [TBL] [Abstract][Full Text] [Related]
38. Synergistic effect of the commonest residual risk factors, remnant cholesterol, lipoprotein(a), and inflammation, on prognosis of statin-treated patients with chronic coronary syndrome. Liu HH; Guo YL; Zhu CG; Wu NQ; Gao Y; Xu RX; Dong Q; Qian J; Dou KF; Li JJ J Transl Med; 2022 May; 20(1):243. PubMed ID: 35619146 [TBL] [Abstract][Full Text] [Related]
39. Measurement of oxidized lipoprotein (a) in patients with acute coronary syndromes and stable coronary artery disease by 2 ELISAs: using different capture antibody against oxidized lipoprotein (a) or oxidized LDL. Wang JJ; Han AZ; Meng Y; Gong JB; Zhang CN; Li K; Liu YX Clin Biochem; 2010 Apr; 43(6):571-5. PubMed ID: 20060390 [TBL] [Abstract][Full Text] [Related]
40. Lipoprotein (a) interactions with cholesterol-containing lipids on angiographic coronary collateralization in type 2 diabetic patients with chronic total occlusion. Shen Y; Chen S; Dai Y; Wang XQ; Zhang RY; Yang ZK; Hu J; Lu L; Ding FH; Shen WF Cardiovasc Diabetol; 2019 Jun; 18(1):82. PubMed ID: 31234867 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]